FRZB and atherosclerosis: The association between adverse events and intermediate SFRP3 levels is further supported when combining intermediate SFRP3 levels and advanced GRACE score, further supports a role for the Wnt pathways in the progression of clinical atherosclerosis involving the regulation of soluble Wnt modulators (160).